Galux was established in 2020 with the incorporation of molecular design technology that has been honed over a period of 15 years at Seoul National University. This technology leverages the integration of AI, physics, and chemistry to produce exceptional results, as evidenced by its performance in the CASP and CAPRI competitions. Built on a foundation of advanced research and development capabilities, Galux is currently developing a drug design platform that incorporates protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction technologies. The company is also focused on identifying and developing novel therapeutics for incurable and rare diseases through its AI-based drug design platform. If you are interested in reaching out to Galux, please do not hesitate to contact us via email at contact@galux.co.kr.
